Strategic Significance:

• CRISPR represents a fundamental shift in biotech, moving from broad medical interventions to precise, programmable genomic medicine. It decouples the mechanism of cutting from the target location, effectively turning biology into software.

Who Should Care:

• Clinicians and biotech investors should care as this shifts the landscape from lifelong symptom management to permanent genetic correction. Ethicists and policy makers must engage because the barrier to editing the germline is technical, not just a matter of intent, making regulation difficult to enforce.

Contrarian Takeaway:

• The most effective way to improve human health through gene editing might not be directly changing human genes, but rather hacking the microbiome of the food systems we depend on—such as engineering cattle-associated microbes to lower methane emissions.